The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

• On March 27, Syros Pharmaceuticals posted weaker-than-expected fourth-quarter results. "We are entering 2024 poised for a major transformation," said Conley Chee, Chief Executive Officer of Syros. "We recently completed enrollment of the 190 patients necessary for our primary endpoint analysis in the SELECT-MDS-1 Phase 3 trial, and we remain on track to report pivotal CR data by the middle of the fourth quarter of this year. We are optimistic about this data, which we believe will further reinforce tamibarotene’s potential as a differentiated, biologically targeted approach for the approximately 50% of HR-MDS patients who are positive for RARA overexpression." The company’s stock fell around 19% over the past five days and has a 52-week low of $2.09.
• RSI Value: 28.27
• SYRS Price Action: Shares of Syros Pharmaceuticals fell 5.8% to close at $5.04 on Monday.